Dr Andreas Makris Publications

 Padhani AR, Makris A, Gall P, Turariu N, de Bono JS. Therapy monitoring of skeletal metastases with whole body difusion MRI. (J Magn Reson Imaging. 2014; 39(5):1049-78).

Sanghera B, Wong WL, Senoda L, Beynon G, Makris A, Woolf D, Ardeshna K. Role of FLT PET-CT in treatment response prediction. ( Indian Journal of Nuclear Medicine 2014; 29: 65-73).

Woolf DK, Beresford M, Li SP, Dowsett M, Sanghera B, Wong WL, Sonoda L, Detre S, Amin V, Ah-See ML, Miles D, Makris A. Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer. Br J Cancer. 2014 May 15. doi: 10.1038/bjc.2014.207. [Epub ahead of print].

OPTIMA Trialists: Bartlett J, Canney P, Campbell A, Cameron D, Donovan J, Dunn J, Earl, H, Francis A, Hall P, Harmer V, Higgins H, Hulme C, Hughes-Davies L, Makris A, Morgan A, McCabe C, Pinder S, Poole C, Rea D, Stallard N, Stein R. Selecting patients for chemotherapy: The opening of the UK OPTIMA trial. (Clinical Oncology 2013; 25: 109-116).Padhani AR, Ree VK, Collins, DJ, D’Sa S, Makris A, Assessing the relationship between bone marrow signal intensity and apparent diffusion coefficient on diffusion weighted MRI. (American Journal of Roentgenology 2013; 200: 163- 170).

Yu Ke-Da, Zhu Rui, Zhan Ming, Rodriguez AA, Yang W, Wong S, Brown P, Makris A., Mayer I, Pietenpol J, Shao Zhi-Ming, Symmans WF, Chang JC. Identification of prognosis-relevant subgroups in patients with chemoresistant triple negative breast cancer. (Clinical Cancer Research 2013; 19 (10): 2723-33).

Van Poznak C, Makris A, Clack G, Barlow D, Eastell R. Lipid profiles within the SABRE Trial of anastrozole with or without risendronate. (Breast Cancer Research and Treatment 2012; 134: 1141-7).

Li, S, Makris A, Gogbashian A, Simcock I, Stirling JJ, Goh V. Predicting response to neoadjuvant chemotherapy in primary breast cancer using volumetric helical perfusion computed tomography: a preliminary study. (European Radiology 2012; 22: 1871-80).

Berruti A, Generali D, Kaufmann M, Puzstai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone MG, Conte PF, Kennedy D, Damia G, Petronini PG, di Cosimo S, Bruzzi P, Dowsett M, Desmedet C, Mansel RE, Marsoni S, Oliveti L, Tondini C, Sapino A, Fenaroli P, Tortora GP, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, da Azambuja E, Makris A, Tampellini M, Dontu G, Van’t Veer L, Harris AL, Fox SB, Dogliotti L, Bottini A. International expert consensus on primary systemic therapy of early breast cancer. Highlights of the third symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy, 2010. (JNCI Monographs 2011; (43): 147-151).

Li SP, Padhani AR, Makris A. DCE-MRI and BOLD-MRI for tumor biology changes under treatment. (JNCI Monographs 2011; 2011 (43): 103-107).

Mehta S, Buffa FM, Li SP, Hughes NP, Adams RF, Adwani A, Taylor NJ, Levitt NC, Padhani AR, Makris A, Harris A. Integrated gene expression and MRI analysis to assess early therapeutic response to bevacizumab in primary breast cancer. (JNCI Monographs 2011; 2011 (43): 71-74).

Leonard R, Ballinger R, Cameron D, Ellis P, Fallowfield L, Gosney M, Johnson L, Kilburn LS, Makris A, Mansi J, Reed M, Ring A, Robinson A, Simmonds P, Thomas, G, Bliss JM. Adjuvant chemotherapy in older women (ACTION) study – What did we learn from the Pilot Phase? (British Journal of Cancer 2011; 105: 1260-1266).

Li SP, Makris A, Beresford MJ, Taylor NJ, Ah-See M-L, Stirling JJ, d’Arcy JA, Collins DJ, Kosarski R, Padhani AR. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy? (Radiology 2011; 260: 68-78).

Li SP, Padhani AR, Taylor NJ, Beresford MJ, Ah-See ML, Stirling JJ, d’Arcy JA, Collins DJ, Makris A. Vascular characterization of triple negative breast carcinomas using dynamic MRI. (European Radiology 2011; 21(7): 1364-73).

Krell J, James CR, Shah D, Gojis O, Lim A, Riddle P, Ahmad R, Hogben K, Makris A, Cowdrey A, Chow A, Babayev T, Madden P, Coombes RC, Leonard R, Cleator S, Palmieri C. Human epidermal growth factor receptor 2 positive breast cancer relapsing post-adjuvant trastuzumab: patterns of recurrence, treatment and outcome. (Clinical Breast Cancer 2011; 11 (3): 153-160).

Beresford MJ, Tumur I, Chakrabarti J, Barden J, Rao N, Makris A. A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors (AIs) in metastatic breast cancer. (Clinical Oncology 2011; 23: 209-215).

Li SP, Taylor NJ, Makris A, Beresford M, Ah-See M-L, Padhani A. Imaging and histologic correlates of intrinsic susceptibility-weighted MRI in primary human breast adenocarcinomas before and during chemotherapy. (Radiology 2010; 257: 643-652).

Rodriguez AA, Makris A, Wu WF, Froehlich A, Dave B, Hilsenbeck SG, Lewis MT, Rimawi M, Osbone CK, Chang JC. Defective DNA repair signature is predictive of anthracycline response in triple negative breast cancer patients. (Journal of Clinical Oncology 2010; 123(1): 189-96).

Van Poznak C, Hannon R, Clack G, Barlow D, Makris A, Eastell R. Prevention of aromatase-induced bone lose using risendronate: The SABRE Trial. (Journal of Clinical Oncology 2010; 28: 967-975).

Li SP, Padhani AR, Beresford MJ, Makris A. Imaging – Advances in breast MRI. (Breast Cancer Forum, October 2009; 1-5).

Makris A. TACT: Implications of a long-awaited trial. Breast Cancer Forum, June 2009: 5-6.

Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early Breast Cancer. (The Lancet 2009; 373: 1463-1479).

Vilarino-Varela M, Chin YS, Makris A. Current indications for post-mastectomy radiation. (Int Semin Surg Oncol. 2009; 6:5).

Beresford MJ, Stott D, Makris A. Assessment of clinical response after 2 cycles of primary chemotherapy in breast cancer. (Breast Cancer Research and Treatment 2008; 109 (2): 337-342).

Ah-See M-L, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ, Stirling JJ, d’Arcy JA, Collins DJ, Pittam MR, Ravichandran D, Padhani AR. Early changes in functional dynamic MRI predict for pathological response to neoadjuvant chemotherapy in primary breast cancer. (Clinical Cancer Research 2008; 14(20): 6580-9).

Chang JC, Makris A, Hilsenbeck SG, Gutierez MC, Hackett JR, Jeong J, Liu M-L, Baker J, Clark-Lagone, Baehmer FL, Sexton K, Mohsin S, Gray T, Alvarez L, Chamness GC, Osborne CK, Shak S. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. (Breast Cancer Research and Treatment 2008; 108: 233-240).

Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eirmann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov, Schneewies A, Souchon R, Stearns V, Untch M, Loibl S. Recommendations from an International Expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives. (Annals of Oncology 2007; 18: 1927-1934).

Gatt A, Makris A, Cladd H, Burcombe RJ, Smith JM, Thompson D, Makris M. Hyperhomocysteinaemia in women with advanced breast cancer. (International Journal of Clinical and Laboratory Haematology 2007; 29: 421-425).

Chin YS, Beresford M, Ravichandran D, Makris A. Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. (The Breast 2007; 16: 436-439).

Beresford M, Lyburn I, Sanghera B, Makris A, Wong WL. Serial integrated 18F-fluorodeoxythymidine PET/CT monitoring neoadjuvant chemotherapeutic response in invasive ductal carcinoma. (The Breast 2007; 13: 424-425).

Benson JR and Querci della Rovere G, and the Axilla Management Consensus Group. Management of the axilla in women with breast cancer. (Lancet Oncology 2007; 8: 331-348).

Makris A. Discussion of the PACS 01 Trial results and their potential impact on clinical practice. (Breast Cancer Forum 2007; 13: 5-6).

Makris A. Targetting HER2 – the story continues (Guest Editorial). Evidentia 2007; 1: 3.

Beresford MJ, Ravichandran D, Makris A. Neoadjuvant endocrine therapy in breast cancer. (Cancer Treatment Reviews 2007; 33: 48-57).

Dr David Miles Publications

Miles D. Management of toxicity in patients receiving therapy with bevacizumab. EJC Suppl 2008;6(6):29-39.

Julien S, Picco G, Sewell R, Vercoutter-Edouart AS, Tarp M, Miles D, Clausen H, Taylor-Papadimitriou J, Burchell JM. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer. 2009 Jun 2;100(11):1746-54.

Miles DW. Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. Breast Cancer Res. 2009;11(4):208.

Kesisis G, Makris A, Miles D. Update on the use of aromatase inhibitors in early-stage breast cancer. Breast Cancer Res. 2009;11(5):211.

Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010 Mar 1;28(7):1138-44.

Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, Baselga J. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1131-7.

Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N, Bhatti R, Shehata M, Nouras H, Camburn T, Johnston SR. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases–the UK experience. Br J Cancer. 2010 Mar 16;102(6):995-1002.
Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, Baselga J. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1131-7.

Chan A, Miles DW, Pivot X. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol. 2010 Mar 24. [Epub ahead of print]

Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010 Jul;122(1):181-8.

Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010 Jul 10;28(20):3239-47.

Palmieri C, Krell J, James CR, Harper-Wynne C, Misra V, Cleator S, Miles D. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol. 2010 Oct;7(10):561-74.

Miles D, Bridgewater J, Ellis P, Harrison M, Nathan P, Nicolson M, Raouf S, Wheatley D, Plummer C. Using Bevacizumab to treat metastatic cancer: UK consensus guidelines. B J Hosp Med Dec 71 (12):634-642

Miles D, Harbeck N, Escudier B, Hurwitz H, Saltz L, Van Cutsem E, Cassidy J, Mueller B, Sirzén F. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol. 2011 Jan 1;29(1):83-8.

Miles D, Roche H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK. Phase III multicentre calinical trials of the Sialyl-TN (STn)-kehole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. The Oncologist 2011 May 16(8) 1092-1100.

Buzdar AU, Xu B, Digumarti R, Goedhals L, Hu X, Semiglazov V, Cheporov S, Gotovkin E, Hoersch S, Rittweger K, Miles DW, O’Shaughnessy J, Tjulandin S; NO16853 trial group. Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Ann Oncol. 2012 Mar;23(3):589-97. Epub 2011 Jun 1.

Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, Ciruelos E, von Moos R, Chang HT, Duenne AA, Miles DW. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO. Eur J Cancer. 2011 Nov;47(16):2387-95. Epub 2011 Jul 15. PubMed PMID: 21757334.

Cortes J, Calvo V, Ramirez-Merino N, O’Shaughnessy J, Brufsky A, Robert N, Vidal M, Munoz E, Perez J, Dawood S, Saura C, Di Cosimo S, Gonzalez-Martin A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol. 2011 Oct 4. [Epub ahead of print] PubMed PMID:21976387.

Coleman RE, Bertelli G, Beaumont T, Kunkler I, Miles D, Simmonds PD, Jones AL, Smith IE. UK Guidance Document: Treatment of Metastatic Breast Cancer. Clin Oncol (R Coll Radiol). 2012 Apr;24(3):169-76. Epub 2011 Nov 8.

Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL,
Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19. PubMed PMID: 22149875.

Cortes J, Caralt M, Delaloge S, Cortes-Funes H, Pierga JY, Pritchard KI,
Bollag DT, Miles DW. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. Eur J Cancer. 2012 Mar;48(4):475-81. Epub 2011 Dec 22.

Miles D, Zielinski C, Martin M, Vrdoljak E, Robert N. Combining capecitabine and bevacizumab in metastatic breast cancer: A comprehensive review. Eur J Cancer. 2012 Mar;48(4):482-91. Epub 2012 Jan 16.